Avalyn Pharma officer proposes $443K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Avalyn Pharma Inc. (AVLN) officer Douglas Carlson reported a proposed sale of 14,875 common shares, with an aggregate market value of $442,680 and an approximate sale date of November 17, 2026. The notice says the shares were acquired from the issuer on November 17, 2026, through exercise of stock options, with cash payment.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Exercise of Stock Options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 date is listed for Douglas Carlson's AVLN sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.